Acromegaly Treatment Market Size, Trends 2020 – Global Industry Share, Growth Analysis, Market Leaders, Business Demand, Application and Fastest CAGR During Forecast Period 2026
SEATTLE, March 24, 2021, (PHARMIWEB) — Global Acromegaly Treatment Market
Acromegaly is a rare disorder caused due to the excess production of growth hormones by the pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually caused by benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can be observed due to ineffective control of growth hormone-secreting cells by hypothalamus. Abnormal enlargement of hands, arms, feet, legs, and head, and gradual changes in facial features such as eye-brow, lower jaw, and nose are visible symptoms of this disorder. Untreated acromegaly leads to serious and life threating complications such as cardiomyopathy and ventricular arrhythmia.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1477
Blood test to measure levels of growth hormones or insulin-like growth factor and imaging of tumors through MRI scan and CT scan are commonly used diagnostic approaches to detect acromegaly. Some medications are 90% effective in shrinking tumor, however, success rate of type of treatment varies based on age, health or medical history of patients. According to the American Society of Clinical Oncology (ASCO), approximately 14,230 individuals in the U.S. were diagnosed with pituitary gland tumors in 2017, and the benign tumor accounted for the majority of these. Furthermore, in 2017, the National Organization for Rare Disorders estimated the prevalence rate of acromegaly as 50 to 70 people per million and 3 new cases occur per million every year, which is expected to increase the demand for acromegaly treatment worldwide.
Global Acromegaly Treatment Market Taxonomy
By Disease Type:
- Ectopic Acromegaly
- Pseudo Acromegaly
By Drug Class:
- Somatostatin Analogs (SSAs)
- Somatuline Depot (Lanreotide)
- Others SSAs
- Dopamine Agonists (DAs)
- Bromocriptine Mesylate (Parlodel)
- Others DAs
- Growth Hormone Receptor Antagonist (GHRAs)
- Somavert (Pegvisomant)
By Route of Administration:
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Acromegaly Treatment Market Research Report: https://bit.ly/3lMe2EV
Global Acromegaly Treatment Market Insights
Introduction of new drugs into the market widens the choice of therapies for doctors and patients. In 2017, Midatech Pharma PLC submitted the clinical trial application in the human study of Q-Octreotide (MTD201) in cancer and acromegaly, which received an oral confirmation from Polish regulators for its approval in January 2018. Furthermore, Chiasma’s new oral maintenance therapy for acromegaly treatment, named Mycapssa, has completed an international Phase 3 trial and is further conducting the trial under a protocol accepted by the European Medicines Agency (EMA) for adult patients with acromegaly. However, expiration of drug patents is likely to hamper the global market growth to some extent.
As acromegaly is a non-preventable disease, early detection of the disease will help to cure the disease symptoms. Increasing awareness to differentiate between acromegaly and other disorders like gigantism, Marfan syndrome, and Pachydermoperiostosis, and further detecting the symptoms and diagnosing it will help in propelling acromegaly treatment market growth. For instance, Acromegaly Awareness Day was celebrated on November 1, 2017 for the first time by World Alliance of Pituitary Organization (WAPO) and Pituitary Network Association to increase awareness on diagnosing the symptoms of this disease without any delay. Some foundation provided financial assistance to medicare patients suffering with acromegaly. For instance, in December 2017, HealthWell Foundation launched a new fund scheme where it provided a fund of US$ 10,000 for a 12-month grant to acromegaly patients who have annual household incomes up to 400 percent of the federal poverty level. Such funding programs will provide financial ease to the patients suffering from acromegaly, which in turn will propel growth of acromegaly treatment market.
In 2017, Crinetics Pharmaceuticals, Inc. was awarded Phase IIB Small Business Innovation Research (SBIR) grant of up to US$ 2.8 million from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) for the development of company’s orally-available, non-peptide somatostatin agonist drug candidate, CRN00808 that can be used for the treatment of acromegaly.
Global Acromegaly Treatment Market – Competitive Scenario
Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline Plc, Midatech Pharma PLC, Strongbridge Biopharma Plc, Chiasma Inc., Aegis Therapeutics LLC, Amryt Pharma Plc, Antisense Therapeutics Ltd, Crinetics Pharmaceuticals Inc., Dauntless Pharmaceuticals Inc., and Ipsen Biopharmaceuticals Inc. are the major players involved in the global acromegaly treatment market.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/acromegaly-treatment-market-1477About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire